To evaluate the current literature for processes of care and outcomes of multimodal therapies for muscleinvasive urothelial carcinoma of the bladder.
INTRODUCTION
Urothelial carcinoma of the bladder remains a significant public health problem in the United States, with over 69 000 expected new cases and an estimated 10 670 deaths due to the disease in 2011 [1] . Known risk factors for the development of urothelial carcinoma include smoking, pelvic radiation, and a number of occupational exposures including aniline dyes, aromatic amines, nitrites, acrolein, coal, and arsenic [2, 3] . Histopathology is of paramount importance in the management of urothelial carcinoma, and as such, careful attention must be paid to depth of invasion. Approximately 70% of new bladder cancer cases fail to invade the detrusor muscle (muscularis propria) and are managed with combination therapy including serial cystoscopy, transurethral resection (TUR), and intravesical chemotherapy and/or immunotherapy. Nonetheless, 50-70% of the nonmuscle invasive tumors will recur and 10-20% will progress to ultimately become muscle invasive [4, 5] . Radical cystectomy, pelvic lymphadenectomy, and urinary diversion remain the gold standard treatment for patients with muscle-invasive urothelial carcinoma (T2þ). Recurrence rates following surgical extirpation remain unacceptably high, between 30 and 45% [6, 7] , with 5-year overall survival following radical cystectomy of 45-66% [6,7,8 & ,9] . Given the modest long-term cure rates from surgical monotherapy, considerable attention has been paid to multimodality treatment for muscle-invasive urothelial carcinoma. This review will discuss the advances in the administration of perioperative
NEOADJUVANT CHEMOTHERAPY FOR MUSCLE-INVASIVE UROTHELIAL CARCINOMA OF THE BLADDER
The past 20 years have witnessed mounting highquality evidence for the administration of cisplatinbased neoadjuvant chemotherapy (NAC) for muscle-invasive urothelial carcinoma. The largest trial, conducted by the Medical Research Council (MRC)/European Organization for Research and Treatment of Cancer (EORTC), randomized 976 patients to radical local therapy or three cycles of neoadjuvant cisplatin, methotrexate, and vinblastine (CMV). At a median follow-up of 8 years, investigators documented a 16% reduction in all-cause mortality and a 23% reduction in death or metastasis in those patients receiving neoadjuvant CMV compared to those undergoing local therapy alone. NAC, in this study, resulted in increased 3-year survival from 50 to 56%, improved 10-year survival from 30 to 36%, and enhanced median survival of 7 months [10 & ]. These findings are consistent with the data from the Southwest Oncology Group (SWOG), who randomized 317 patients to immediate radical cystectomy or three cycles of neoadjuvant methotrexate, vinblastine, doxorubicin, and cisplatin followed by radical cystectomy. At a median follow-up of 8.7 years, patients receiving neoadjuvant MVAC enjoyed a median survival of 77 months, compared to 46 months in the immediate cystectomy group. Proportional hazards modeling revealed a 33% increase in the risk of death among patients in the immediate cystectomy cohort when compared to those receiving neoadjuvant MVAC [11] .
In addition to the SWOG and MRC/EORTC trials, pooled data from the Nordic Collaborative Group evaluated survival following neoadjuvant cisplatin/doxorubicin or cisplatin/methotrexate and confirmed a 20% improvement in risk of death, favoring the NAC cohort. This combined analysis showed an absolute survival benefit of 8% at 5 years [12]. These data have been corroborated by a metaanalysis performed by the Advanced Bladder Cancer Meta Analysis Collaboration who documented a 5% absolute overall survival benefit conferred to those patients receiving cisplatin-based NAC compared to those not receiving chemotherapy. These data demonstrated a 5-year survival of 50 and 45%, respectively.
Despite the preponderance of evidence favoring the use of NAC, utilization of this strategy has been poor. Recent data from the National Cancer Database revealed only 9% of patients received NAC. However, the rate of administration did increase from 6% in 2003 to 13% in 2007, likely reflecting the incorporation of randomized trial data into clinical practice [13 & ]. Numerous studies from both the USA and Canada have corroborated the dismal rates of utilization [14, 15] , prompting the identification of referral for NAC as a quality measure in bladder cancer care. Possible reasons for the low uptake of the neoadjuvant paradigm include potential concerns for overtreatment of low-risk patients, surgical delay in chemotherapy nonresponders, and concerns over rendering elderly patients unsuitable for radical cystectomy [16] . Systems-based quality improvement efforts must be undertaken to improve delivery of NAC to appropriate patients with muscle-invasive bladder cancer.
ADJUVANT CHEMOTHERAPY
The data supporting the administration of adjuvant chemotherapy for urothelial carcinoma are less robust than the corresponding data for NAC. Nonetheless, many physicians treating muscle-invasive bladder cancer favor this approach given the ability of pathologic staging to further stratify patients into risk groupings for likelihood of progression. Furthermore, adoption of an adjuvant paradigm facilitates the separation of patients with pT2 disease from
KEY POINTS
Five-year overall survival for muscle-invasive urothelial carcinoma of the bladder after radical cystectomy is between 45 and 66%.
Neoadjuvant chemotherapy confers a 6-8% survival advantage over the same timeframe, although it is dramatically underutilized.
Adjuvant chemotherapy provides similar survival advantage, yet as many as 64% of patients may experience a posttreatment complication.
Transurethral resection and concomitant chemotherapy can provide 5-year survival rates comparable to radical cystectomy in select patients; nonetheless, residual tumor rates may be alarmingly high.
Trimodal therapy, employing transurethral resection, radiation treatment, and chemotherapy, results in similar 5-year survival rates to radical cystectomy; however, patients with disease recurrence and an intact bladder may have significantly worse survival.
Grade III pelvic complications from trimodal therapy occur in 2-6% of patients.
those with pT3, pT4, or node positive disease, each of whom is at high risk of progression [4] .
Given the limitations of available level I evidence including small sample sizes, variable chemotherapeutic regimens, short follow-up, and early study termination, the most widely cited evidence evaluating adjuvant platinum-based chemotherapy is a meta-analysis conducted by the Advanced Bladder Cancer Consortium. This systematic review included 491 patients from six trials representing 90% of all patients randomized to adjuvant cisplatin-based combination trials. This study revealed a 25% relative decrease in the risk of all-cause mortality in patients who received adjuvant chemotherapy, corresponding to an absolute survival benefit of 9%. Additionally, these data revealed a 32% relative improvement in disease-free survival, corresponding to an absolute benefit of 12% [17] . The Advanced Bladder Cancer (ABC) investigators caution that the small number of patients in this series limits the analysis, and as such, they state that there is insufficient evidence upon which to base treatment decisions. Although these data may be somewhat limited, nonrandomized observational data have corroborated the survival benefit documented in the ABC meta-analysis [18 & ]. The adjuvant chemotherapy paradigm poses a unique set of challenges in patients with advanced bladder cancer. Recent data suggest high rates of perioperative morbidity, with 64% of patients suffering a complication [19] and 26.6% requiring readmission [20 & ] within 90 days of surgery. Indeed, impairments in functional status following cystectomy have been shown to prevent the administration of adjuvant chemotherapy in nearly 30% of patients [19, 21] . These data must be considered when discussing the merits of combined multimodality treatment for muscle-invasive bladder cancer.
ORGAN PRESERVATION
Despite the aforementioned advances realized by combination chemotherapy and radical cystectomy for muscle-invasive urothelial carcinoma, many patients are too ill or unwilling to undergo radical surgery. Progress in multimodal treatment for carcinomas of the breast, larynx, rectum, esophagus, and extremity soft-tissue sarcomas has fostered interest in organ preservation for urothelial carcinoma [22, 23] . Notwithstanding concerns regarding the multifocality and high rate of concomitant upper tract disease [24] , rates of overall survival between radical cystectomy and strategies employing multimodal treatments with salvage cystectomy are similar [25] [26] [27] .
RADICAL TRANSURETHRAL RESECTION OR PARTIAL CYSTECTOMY PLUS CHEMOTHERAPY
In light of the improvements in all-cause mortality attributed to NAC regimens, several investigators have explored the role of bladder preservation in those select patients who achieve complete clinical response (cT0) on restaging TUR after NAC. In 1998, Herr et al. [28] evaluated 111 patients with muscle invasive urothelial carcinoma, 54% of whom achieved a cT0 response on restaging TUR after prior chemotherapy. Of this group, 72% opted for bladder preservation. At the completion of 10 years of follow-up, 74% were alive and 58% had an intact bladder. By comparison, only 65% of the radical cystectomy patients were alive at the completion of follow-up. As with many studies, it is difficult to ascertain whether these differences were due to treatment effect or confounding by indication. In a further analysis, deVere White et al. [29] evaluated 77 patients who received three cycles of gemcitabine, paclitaxel, and carboplatin for muscle-invasive bladder cancer. After restaging TUR, 46% achieved an apparent complete clinical response. Of this subset, 33% received prompt cystectomy, which noted a disturbingly high proportion (60%) of residual tumor in the bladder specimen. Despite the mitigating fact that these patients received nonplatinum-based chemotherapy, the authors urge consideration to definitive local therapy despite apparent cT0 pathology.
In 2011, Koga et al.
[30 & ] evaluated 183 patients with muscle-invasive urothelial carcinoma, 83 of whom were considered initial candidates for partial cystectomy, based on post-TUR criteria of small volume and well circumscribed tumors that did not involve the bladder neck or trigone. This subset then received concurrent cisplatin and radiotherapy over 4 weeks to 40 Gy total. A total of 65 patients ultimately underwent partial cystectomy with pelvic lymph node dissection, 71% of whom remained with an intact bladder. The remainder underwent completion cystectomy because of persistent muscle-invasive disease. In the highly selected partial cystectomy cohort, 5-year cancer-specific survival (CSS) and recurrence-free survival were both 100% after a median follow-up of 45 months.
TRIMODAL THERAPY: TRANSURETHRAL RESECTION, RADIATION THERAPY, AND CHEMOTHERAPY
Despite the successes noted in bimodal strategies, the most common approach to bladder preservation has utilized trimodal therapy. Selection criteria for this paradigm should assess tumor histology, stage, hydronephrosis, multifocality, presence of carcinoma in situ, extent of tumor, and existence of disease outside the bladder [31] . Management is initiated with an aggressive TUR, with an aim for complete tumor resection. This is followed by external beam radiation to the pelvis, with dosing to 40-45 Gy and concomitant radiosensitizing chemotherapy, such as 5-fluorouracil, cisplatin, gemcitabine, or paclitaxel. The addition of chemotherapy has the dual benefit of enhancing the radiotherapy and systemically treating micro-metastatic disease [32] . After completion of this course of treatment, patients proceed to repeat TUR. Those with persistent disease are typically referred for cystectomy, whereas responders often receive an additional radiation course of 20-25 Gy. Cystoscopic surveillance continues at 3-6 months intervals. These protocols have largely been developed at Massachusetts General Hospital (MGH) and via cooperative institutions such as the Radiation Therapy Oncology Group (RTOG) [33] .
RTOG 85-12 was the initial trial to introduce this standardized trimodal paradigm. In a cohort of 42 patients, 4-year survival was 64% utilizing concomitant cisplatin and induction radiotherapy of 40 Gy. As delineated above, responders were allocated to further radiotherapy, whereas those patients with persistent disease were referred for cystectomy [34] . In a follow-up series, RTOG 95-06, 34 patients with muscle invasive bladder cancer received complete TUR, combination cisplatin and 5-fluorouracil, and twice-a-day radiotherapy at 3 Gy per fraction for a total dose of 24 Gy. Those patients with complete clinical response received consolidation chemotherapy and repeat radiation to a total dose of 44 Gy. A total of 67% of patients had clinical resolution of disease with 83% survival at 3 years [35] .
More recently, investigators have evaluated the addition of alternative chemotherapeutic agents such as gemcitabine and paclitaxel. In a series of 80 patients receiving concomitant cisplatin and paclitaxel with hyperfractionated radiotherapy to 21 Gy, the complete response rate was 81%. Responders received adjuvant gemcitabine with cisplatin and consolidation radiotherapy to 45 Gy total. Actuarial 5-year overall survival was 56% and disease-specific survival was 71% [36] . Similarly, in 2011, Caffo et al. [37 & ] presented the combined results of two small, prospective trials, totaling 26 patients, who received concurrent gemcitabine and cisplatin with fractionated radiotherapy to 54 Gy. Actuarial 5-year overall survival in this series was 70% with a disease-specific survival of 79% and an intact bladder proportion of 74%.
SUPERFICIAL RECURRENCE AFTER TRIMODAL TREATMENT
Regardless of the type of treatment, patients with a diagnosis of urothelial carcinoma and an intact bladder require vigilant follow-up. For those patients with persistent or recurrent muscle invasive bladder cancer, the recommendation is to proceed to radical cystectomy. The data are less clear on the best course of management for superficial disease recurrence after trimodal therapy. In 2003, Pieras et al. [38] evaluated a select cohort of 51 patients who underwent bladder preservation with bimodal TUR and carboplatin with vinblastine. A total of 82% of these patients were considered responders and elected bladder preservation. Of this group, 18 patients (43%) were noted to have superficial recurrence at the time of referral for bladder preservation. The authors noted no difference in CSS between those patients with superficial recurrence (94% CSS) compared to those without disease recurrence (89% CSS). Comparably, Zietman et al. [39] in a series of 190 patients enrolled at Massachusetts General Hospital and treated with trimodal therapy noted a 26% rate of superficial recurrence and also found no significant difference in 5-year survival between those with superficial recurrence and those that remained free of disease. Importantly, however, after 8 years of follow-up, 61% of recurrence-free patients were alive with an intact bladder, while survival with a functional bladder was a mere 34% for those with superficial recurrence. Thus, the management of patients with superficial recurrence after bladder preservation remains a clinical quandary.
PELVIC TOXICITY AFTER BLADDER-PRESERVING THERAPIES
The benefits of bladder-sparing therapies are manifest only if they outweigh the risks. Evidence from quality-of-life studies suggest that patients undergoing bladder preservation enjoy continued appropriate bladder function and sustained sexual function after treatment [40] . Not surprisingly, given their leadership role, researchers at RTOG and MGH have described their experience with complications after trimodal therapy. In 285 patients after a mean follow-up of 5.4 years, 6% of patients experienced late grade III genitourinary toxicities, such as frequency and dysuria, whereas less than 2% of patients experienced late grade III bowel toxicities, such as diarrhea or colic. The median duration of these complications was 7 months, which typically decreased over time. Importantly, there were no late grade IV complications, such as severe hemorrhagic cystitis or bowel necrosis in this series. No patients required a cystectomy because of treatment-associated complications [41] .
FUTURE DIRECTIONS
'The overarching goal of personalized medicine is to optimize medical care and outcomes for each individual, to include treatments, medication types and dosages, and/or prevention strategies that may differ from person to person -resulting in an unprecedented customization of patient care' [42] . The future key to multimodal therapy will be the ability to precisely and prospectively determine those individuals at highest risk for disease progression and mortality, so that they can be targeted for more aggressive approaches. To this end, future treatment strategies for various solid tumors will incorporate a personalized approach based upon molecular diagnostic tools to predict risk of recurrence, progression, and response to specific therapeutic agents. Investigators have already begun to develop molecular instruments to better identify patients at high risk for nodal disease. Smith et al. [43] recently reported the validation of a geneexpression model (GEM) for the prediction of nodal metastasis at the time of radical cystectomy. When incorporated into a multivariable model comprising known predictors of nodal disease, the gene-expression score remained highly predictive of the presence of lymph node metastases. Shah et al. [44 & ] recently described the dual challenges of improving the paradigm by which we treat bladder cancer -enhancing our ability to accurately stage patients and refining our ability to predict which patients will respond to particular chemotherapy regimens. Progress in pretreatment risk-stratification and prediction of individual tumor response will allow practitioners to tailor treatment strategies to individual patients' risk profiles, predicted response, treatment goals, and specific utility functions.
CONCLUSION
It has been repeatedly demonstrated in multiple series that urothelial carcinoma is responsive to both chemotherapy and radiation. The challenge has been two-fold -to determine in which patients these modalities should be added to, or replace, radical surgery and the optimal timing of these alternate treatment strategies. The key to solving these choices will be further work through properly conducted randomized trials and additional efforts to accurately and reliably assess an individual's disease-related risk. 
